Clinical Trial

A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Dimensions: NCT03675308

Investigators

Affiliations

Organisations

  1. (1) AbbVie (United States), grid.431072.3

Sponsors/collaborators

Abstract

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).

Methods

Condition: Psoriatic Arthritis

Intervention: Risankizumab administered by subcutaneous (SC) injection

Recruitment information

Gender: All

Trial period

2019-2024

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry